PDF(Pubmed)
Abstract：
UNASSIGNED: In randomized clinical trials (RCTs) investigating the application of transcranial alternating current stimulation (tACS) in schizophrenia, inconsistent results have been reported. The purpose of this exploratory systematic review of RCTs was to evaluate tACS as an adjunct treatment for patients with schizophrenia based on its therapeutic effects, tolerability, and safety.
UNASSIGNED: Our analysis included RCTs that evaluated adjunctive tACS\' effectiveness, tolerability, and safety in schizophrenia patients. Three independent authors extracted data and synthesized it using RevMan 5.3 software.
UNASSIGNED: Three RCTs involving 76 patients with schizophrenia were encompassed in the analysis, with 40 participants receiving active tACS and 36 receiving sham tACS. Our study revealed a significant superiority of active tACS over sham tACS in improving total psychopathology (standardized mean difference [SMD] = -0.61, 95% confidence interval [CI]: -1.12, -0.10; I2 = 16%, p = 0.02) and negative psychopathology (SMD = -0.65, 95% CI: -1.11, -0.18; I2 = 0%, p = 0.007) in schizophrenia. The two groups, however, showed no significant differences in positive psychopathology, general psychopathology, or auditory hallucinations (all p > 0.05). Two RCTs examined the neurocognitive effects of tACS, yielding varied findings. Both groups demonstrated similar rates of discontinuation due to any reason and adverse events (all p > 0.05).
UNASSIGNED: Adjunctive tACS is promising as a viable approach for mitigating total and negative psychopathology in individuals diagnosed with schizophrenia. However, to gain a more comprehensive understanding of tACS\'s therapeutic effects in schizophrenia, it is imperative to conduct extensive, meticulously planned, and well-documented RCTs.
UNASSIGNED: Our analysis included RCTs that evaluated adjunctive tACS\' effectiveness, tolerability, and safety in schizophrenia patients. Three independent authors extracted data and synthesized it using RevMan 5.3 software.
UNASSIGNED: Three RCTs involving 76 patients with schizophrenia were encompassed in the analysis, with 40 participants receiving active tACS and 36 receiving sham tACS. Our study revealed a significant superiority of active tACS over sham tACS in improving total psychopathology (standardized mean difference [SMD] = -0.61, 95% confidence interval [CI]: -1.12, -0.10; I2 = 16%, p = 0.02) and negative psychopathology (SMD = -0.65, 95% CI: -1.11, -0.18; I2 = 0%, p = 0.007) in schizophrenia. The two groups, however, showed no significant differences in positive psychopathology, general psychopathology, or auditory hallucinations (all p > 0.05). Two RCTs examined the neurocognitive effects of tACS, yielding varied findings. Both groups demonstrated similar rates of discontinuation due to any reason and adverse events (all p > 0.05).
UNASSIGNED: Adjunctive tACS is promising as a viable approach for mitigating total and negative psychopathology in individuals diagnosed with schizophrenia. However, to gain a more comprehensive understanding of tACS\'s therapeutic effects in schizophrenia, it is imperative to conduct extensive, meticulously planned, and well-documented RCTs.
摘要：
■在研究经颅交流刺激（tACS）在精神分裂症中的应用的随机临床试验（RCT）中，报告了不一致的结果。这项对RCT的探索性系统评价的目的是根据其治疗效果评估tACS作为精神分裂症患者的辅助治疗。耐受性,和安全。
■我们的分析包括评估辅助tACS有效性的随机对照试验，耐受性,以及精神分裂症患者的安全性。三个独立作者提取数据并使用RevMan5.3软件进行合成。
■分析了涉及76名精神分裂症患者的三项随机对照试验，40名参与者接受主动tACS，36名参与者接受假tACS。我们的研究表明，在改善总精神病理学方面，主动tACS优于假tACS（标准化平均差[SMD]=-0.61，95％置信区间[CI]：-1.12，-0.10；I2=16％，p=0.02）和阴性精神病理学（SMD=-0.65，95％CI：-1.11，-0.18；I2=0％，p=0.007）在精神分裂症中。两组,然而,在积极的精神病理学上没有显着差异，一般精神病理学，或幻听（所有p>0.05）。两个RCT检查了tACS的神经认知效应，产生不同的发现。两组由于任何原因和不良事件而停药的发生率相似（均p>0.05）。
■辅助tACS有望成为缓解精神分裂症患者总体和消极精神病理学的可行方法。然而,为了更全面地了解tACS在精神分裂症中的治疗效果，必须广泛开展，精心策划,和有据可查的RCT。
■我们的分析包括评估辅助tACS有效性的随机对照试验，耐受性,以及精神分裂症患者的安全性。三个独立作者提取数据并使用RevMan5.3软件进行合成。
■分析了涉及76名精神分裂症患者的三项随机对照试验，40名参与者接受主动tACS，36名参与者接受假tACS。我们的研究表明，在改善总精神病理学方面，主动tACS优于假tACS（标准化平均差[SMD]=-0.61，95％置信区间[CI]：-1.12，-0.10；I2=16％，p=0.02）和阴性精神病理学（SMD=-0.65，95％CI：-1.11，-0.18；I2=0％，p=0.007）在精神分裂症中。两组,然而,在积极的精神病理学上没有显着差异，一般精神病理学，或幻听（所有p>0.05）。两个RCT检查了tACS的神经认知效应，产生不同的发现。两组由于任何原因和不良事件而停药的发生率相似（均p>0.05）。
■辅助tACS有望成为缓解精神分裂症患者总体和消极精神病理学的可行方法。然而,为了更全面地了解tACS在精神分裂症中的治疗效果，必须广泛开展，精心策划,和有据可查的RCT。
